Alzheimer's Diagnostic Guideline Validation: Exploration of Next Steps: Workshop Summary

摘要

The Institute of Medicine (IOM) Forum on Neuroscience and Nervous System Disorders planned and hosted a 2-hour public workshop at the 2011 Alzheimers Association International Conference (AAIC). Held in Paris, France, on July 18, 2011, the session brought together key stakeholders to discuss next steps in the validation of the new diagnostic guidelines for Alzheimer's disease (AD), specifically, the revised guidelines recently proposed in papers by the International Working Group for New Research Criteria for the Diagnosis of Alzheimer's Disease, and three working groups under the auspices of the National Institute on Aging (NIA) and the Alzheimer's Association. Gabrielle Silver, global strategic marketing leader for neurology at GE Healthcare, charged invited panelists and session participants to consider the similarities and differences between the two proposed diagnostic guidelines; and the lessons learned from the validation of biomarkers for cardiovascular disease that may be relevant to AD, including strategies used in the adoption of the new technology, incorporation of biomarker testing in clinical practice, and impact of targeting a surrogate marker of disease incidence; and the studies needed for validation and standardization of biomarkers for diagnosing pre-dementia and predicting progression to the dementia phase of AD.